Qu Biologics
Founded Year
2007Stage
Grant - III | AliveTotal Raised
$25.89MAbout Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI) that aim to restore the body's normal immune response. It stimulates an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and immune-related disease. The company was founded in 2007 and is based in Burnaby, Canada.
Missing: Qu Biologics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Qu Biologics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Qu Biologics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Qu Biologics is included in 3 Expert Collections, including Cancer.
Cancer
4,784 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Qu Biologics Patents
Qu Biologics has filed 20 patents.
The 3 most popular patent topics include:
- Immunology
- Clusters of differentiation
- Immune system
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/26/2017 | 1/18/2022 | Immune system, Clusters of differentiation, Cytokines, Immunology, Transcription factors | Grant |
Application Date | 4/26/2017 |
|---|---|
Grant Date | 1/18/2022 |
Title | |
Related Topics | Immune system, Clusters of differentiation, Cytokines, Immunology, Transcription factors |
Status | Grant |
Latest Qu Biologics News
Apr 28, 2023
DUBLIN--(BUSINESS WIRE)--The "Microbiome - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This "Microbiome- Competitive landscape, 2023" report provides comprehensive insights about 130+ companies and 180+ drugs in Microbiome Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights In April 2023, A
Qu Biologics Frequently Asked Questions (FAQ)
When was Qu Biologics founded?
Qu Biologics was founded in 2007.
Where is Qu Biologics's headquarters?
Qu Biologics's headquarters is located at 4475 Wayburne Drive, Burnaby.
What is Qu Biologics's latest funding round?
Qu Biologics's latest funding round is Grant - III.
How much did Qu Biologics raise?
Qu Biologics raised a total of $25.89M.
Who are the investors of Qu Biologics?
Investors of Qu Biologics include Industrial Research Assistance Program, National Research Council Canada and Genome British Columbia.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.